1. STING inhibitors target the cyclic dinucleotide binding pocket.
- Author
-
Ze Honga, Jiahao Meia, Chenhui Lia, Guohui Baib, Munire Maimaiti, Haiyang Hu, Wenying Yu, Li Sun, Lele Zhang, Dan Cheng, Yixian Liao, Senlin Li, Yanping You, Hongbin Sun, Jing Huang, Xing Liu, Judy Lieberman, and Chen Wang
- Subjects
TYPE I interferons ,HUMAN herpesvirus 1 ,GAIN-of-function mutations - Abstract
Cytosolic DNA activates cGAS (cytosolic DNA sensor cyclic AMPGMP synthase)-STING (stimulator of interferon genes) signaling, which triggers interferon and inflammatory responses that help defend against microbial infection and cancer. However, aberrant cytosolic self-DNA in Aicardi–Goutière’s syndrome and constituently active gain-of-function mutations in STING in STING-associated vasculopathy with onset in infancy (SAVI) patients lead to excessive type I interferons and proinflammatory cytokines, which cause difficult-to-treat and sometimes fatal autoimmune disease. Here, in silico docking identified a potent STING antagonist SN-011 that binds with higher affinity to the cyclic dinucleotide (CDN)-binding pocket of STING than endogenous 2′3′-cGAMP. SN-011 locks STING in an open inactive conformation, which inhibits interferon and inflammatory cytokine induction activated by 2′3′-cGAMP, herpes simplex virus type 1 infection, Trex1 deficiency, over expression of cGAS-STING, or SAVI STING mutants. In Trex1−/− mice, SN-011 was well tolerated, strongly inhibited hallmarks of inflammation and autoimmunity disease, and prevented death. Thus, a specific STING inhibitor that binds to the STING CDN-binding pocket is a promising lead compound for STING-driven disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF